Share 'Marathon Pharmaceuticals Pauses Commercialization of EMFLAZA™ (deflazacort)'
UPDATE: February 13, 2017, 5:10 PM -- An additional statement from Marathon has been added to the blog
Today, Marathon Pharmaceuticals announced that they will pause the commercialization of their recently FDA-approved steroid EMFLAZA™ (deflazacort) (see 'Statement from Marathon Pharmaceuticals CEO Jeffrey Aronin' below).
This pause will allow Marathon to consider the fee…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this